Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier.
Monoclonal antibodies penetrate bulky tumors poorly after intravenous administration, in part because of specific binding to the target antigen. Experiments presented here demonstrate an analogous phenomenon in micrometastases; poor antibody penetration, attributable to a "binding-site barrier" phenomenon, can be seen in guinea pig micrometastases as small as 300 microns in diameter. Increasing the dose of antibody can partially overcome this limitation, but at a cost in specificity.
Saga
T
T
Nuclear Medicine Department, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Neumann
R D
RD
Heya
T
T
Sato
J
J
Kinuya
S
S
Le
N
N
Paik
C H
CH
Weinstein
J N
JN
D000818:Animals; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000627:therapeutic use; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000918:Antibody Specificity; D001345:Autoradiography; D001650:Bile Duct Neoplasms / Q000473:pathology*; D002277:Carcinoma / Q000628:therapy*; D006168:Guinea Pigs; D007150:Immunohistochemistry; D007167:Immunotherapy / Q000379:methods*; D008168:Lung / Q000473:pathology; D008175:Lung Neoplasms / Q000556:secondary / Q000628:therapy*
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm